Hershey Medical Center Research Trials: February 2025 (Crohn’s, Celiac, and Ulcerative Colitis)
Crohn’s Disease
M24-885: A PHASE 2A MULTICENTER, RANDOMIZED, PLATFORM STUDY OF TARGETED THERAPIES FOR THE TREATMENT OF ADULT SUBJECTS WITH MODERATE TO SEVERE CROHN’S DISEASE. (Abbvie)
Status: Active Trial
Study contact:
Please scan the QR code below, visit this link, or contact Stella at 717-531-8259 if interested in learning more about this study.
CELIAC DISEASE
DOSE-RANGING STUDY OF THE EFFICACY AND SAFETY OF TAK-101 FOR PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET. (Takeda)
Status: Active Trial
Study contact:
Please scan the QR code below, visit this link, or contact Stella at 717-531-8259 if interested in learning more about this study.
ULCERATIVE COLITIS
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABX464 ONCE DAILY FOR INDUCTION TREATMENT IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS. (Abivax)
A RANDOMIZED, DOUBLE-BLIND, MULTICENTER PHASE III STUDY TO EVALUATE THE LONG-TERM EFFICACY AND SAFETY OF ABX464 25 MG OR 50 MG ONCE DAILY AS A MAINTENANCE THERAPY IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS. NOTE: This study will recruit patients who completed the Induction study above (Abivax)
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, 2-PART PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF GS-1427 IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC). (GILEAD)
Status: Active Trials
Study contact:
Please scan the QR code below, visit this link, or contact Stella at 717-531-8259 if interested in learning more about this study.
